Islamabad: The Government of Pakistan on Friday officially launched the historic two-day Pakistan-China Pharmaceutical and Healthcare B2B Investment Conference.
Conceived as a premium, project-driven facilitation initiative, the conference is organized by the Ministry of National Health Services, Regulations and Coordination (NHSRandC), the Drug Regulatory Authority of Pakistan (DRAP), the Trade Development Authority of Pakistan (TDAP), and the Board of Investment (BOI).
The summit brings together a magnificent assembly of over 450 companies under one roof, including over 300 leading Pakistani firms and 150 elite Chinese industrial groups.
Proving the project-driven nature of the alliance, the launching ceremony culminated in an immediate, landmark Exchange of Official Agreements.
Moving decisively past general trade understandings, the summit finalized nine ground-breaking commercial agreements totaling an extraordinary USD 446 million in immediate investment value.
These partnerships represent concrete operational commitments across critical sub-sectors.
Federal Minister for National Health Services, Syed Mustafa Kamal presented an executive brief on the intensive groundwork that enabled the summit.
Minister Kamal transitioned the bilateral narrative into a bold, operational mandate. He said, “Today is not a day for mere diplomatic rhetoric; it is a day of execution.”
He noted that the Ministry and DRAP worked day and night for two months alongside the Pakistan Embassy in Beijing to run compatibility audits, pre-mapping companies to precisely bridge market gaps.
He detailed the seven core localized tracks optimized for investment, spanning APIs, high-precision medical devices, and advanced biotherapeutics.
Emphasizing China’s unwavering commitment to building an even closer China-Pakistan community with a shared future in the new era, the Chinese Ambassador to Pakistan, Jiang Zaidong, delivered a powerful message of solidarity and joint industrial growth.”
He said, “Our All-Weather Strategic Cooperative Partnership with Pakistan remains unbreakable, and healthcare is a vital pillar of this enduring bond.”
He said, “China stands ready to fully align technological strengths with Pakistan’s healthcare requirements under CPEC Phase 2.0.”
He said this B2B conference is not just about commercial transactions as it represents a deep strategic commitment to technology transfer and capacity building.
He said by establishing localized joint ventures, we are not only enhancing Pakistan’s healthcare self-reliance but are also building a resilient, high-tech export corridor that will serve the entire region.
He said the Chinese corporate sector enters this alliance with long-term trust, high-end science, and an absolute commitment to joint prosperity.
In a massive boost to localized preventative medicine, OBS partnered with Chinese biotech giant CanSino Biologics to execute an immediate USD 50 million agreement dedicated to the local manufacturing of the Pneumococcal Conjugate Vaccine (PCV13).
Concurrently, AGP finalized a USD 50 million joint venture with Shanghai United Cell Biotechnology (SUCB), this landmark project will focus on local cell-line development and advanced biotechnology manufacturing for Recombinant Human Growth Hormone (Genheal®), Teriparatide (OstioGen®), and the Oral Cholera Vaccine.
Expanding localized access to critical generic injectables and family planning technologies, OBS Pharma signed a USD 50 million joint venture with Liaoning Ludan Pharmaceutical to establish a domestic manufacturing setup for Levonorgestrel Contraceptive Implants over a 2-year execution timeline.
In the biotherapeutic domain, Genix Pharma Pvt Ltd executed a USD 23 million agreement with a high-tech Chinese consortium comprising Intellective Biologics (Suzhou) Co., Ltd., Nanjing Cellnuo Biopharmaceutical Co., Ltd., and Tofflon Science and Technology Group Co., Ltd. to establish Pakistan’s first internationally integrated biopharmaceutical manufacturing platform for monoclonal antibodies, peptide therapeutics, insulin products, and future biological medicines.
The medical devices and diagnostic landscape witnessed a major transformation as Lab Diagnostic Systems (SMC) Pvt. Ltd. (LDS) signed a USD 25 million collaboration agreement with Chongqing LianXin ZhiKang Biotechnology Co., Ltd. for the localization, registration, assembly, manufacturing, marketing, and distribution of Continuous Glucose Monitoring (CGM) products in Pakistan and selected export markets.
In the largest individual financial commitment of the day, Lab Diagnostic Systems (SMC) Pvt. Ltd. (LDS) further expanded its portfolio by executing a monumental USD 200 million agreement with Sinovac Holding Group Co., Ltd. to collaborate on product registration, commercialization, and phased localization of selected critical vaccines.
Upstream raw material autonomy was firmly addressed by Citi Pharma Limited, which entered into a USD 10 million strategic collaboration with Yangtze River Pharmaceutical Group for technology transfer, knowledge sharing, investment, and localized synthesis of selected Active Pharmaceutical Ingredients (APIs) in Pakistan.
Concurrently, Lucky Core Industries Limited formalized a USD 13 million agreement with HuaHui Health (Hong Kong) Co., Limited aimed at accelerating direct patient access to Libevitug for the treatment of Hepatitis Delta.
Rounding out the historic text, Weatherfolds Pharmaceuticals and Welcome Pakistan Pvt. Ltd. partnered with Tian Yuan Pharmaceutical Co., Ltd to establish an immediate USD 25 million project.
This landmark initiative will build Pakistan’s very first manufacturing facility utilizing advanced synthetic technology for the production of highly sought-after Semaglutide and Tirzepatide APIs as well as their finished pharmaceutical forms.
The launching ceremony also featured strategic diplomatic and industrial addresses, including speeches by the Chinese Ambassador to Pakistan, Jiang Zaidong, and the Special Assistant to the Prime Minister on Industries and Production, Haroon Akhtar Khan.
Following the official exchange of documents, the conference immediately transitioned into the first of three highly anticipated, structured B2B matchmaking sessions.
To sustain this investment velocity, live Information and Facilitation Desks staffed by active directors from DRAP, BOI, and SIFC are operating directly inside the venue boardrooms to assess, facilitate, and clear regulatory inquiries and licensing tracks in real-time.
Day two of the technical sessions will commence with a masterclass led by DRAP, focusing on its global regulatory alignment with WHO and ICH criteria and its seamless integration with the Pakistan Single Window (PSW), before concluding with the finalization of subsequent corporate MoUs.